tamoxifen,Exemestane,Triptorelin
Astrazeneca,Pfizer,Azurity Pharmaceuticals
['breast']
dana-farber's meredith regan, scd ( ), presents research looking at early treatment effects of adjuvant endocrine therapy for high-risk breast cancer from the soft/text trials at #asco22. cc: 
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: media@dfci.harvard.edu or 617-632-4090